Cancer Communications
indexed by SCI
BMC

Efficacy of transcatheter arterial chemoembolization combined with cytokine-induced killer cell therapy on hepatocellular carcinoma: a comparative study
Ming-Zhi Hao , Hai-Lan Lin, Qiang Chen, Yun-Bin Ye , Qi-Zhong Chen, Ming-Shui Chen
Department of Interventional Radiology, Fujian Provincial Tumor Hospital, Fuzhou, Fujian 350014, P. R. China. cqiang8@pub5.fz.fj.cn
[Abstract] Background and Objective: Cytokine-induced killer (CIK) cells have high anti-tumor activity for hepatocellular carcinoma (HCC). Whether CIK cell therapy can eradicate residual cancer cells and prevent or postpone tumor relapse after transcatheter arterial chemoembolization (TACE) should be testified. This study was to evaluate the efficacy of CIK cell therapy combined with TACE on HCC. Methods: A total of 146 consecutive patients with unresectable HCC were divided into combination group (72 patients treated with CIK cell therapy combined with TACE) and TACE group (74 patients treated only with TACE). The progression-free survival (PFS) and overall survival (OS) were analyzed. Results: The 6-month, 1-year, and 2-year PFS rates were 72.2%, 40.4%, 25.3% in combination group, and 34.8%, 7.7%, 2.6% in TACE group. The median time to progression was 11 months [95% confidence interval (CI), 8-14 months] in combination group and 5 months (95% CI, 4-7 months) in TACE group. The estimated 6-month, 1-year, and 2-year OS rates were 90.3%, 71.9%, 62.4% in combination group, and 74.6%, 42.8%, 18.8% in TACE group. The median OS was 31 months (95% CI, 27-35 months) in combination group and 10 months (95% CI, 7-13 months) in TACE group. The times of TACE, ECOG performance status, and CIK cell therapy were independent prognostic factors for PFS and OS. Conclusion: Adjuvant immunotherapy with CIK cells could greatly improve the efficacy of TACE on HCC, and plays an important role in prolonging the PFS and OS of HCC patients after TACE.
Chinese Journal of Cancer 2010, Volume: 29, Issue 2, Page: 172-
[ PDF Full-text ]
[Google Scholar]


SHARE THIS ARTICLE


Your Comments

  

 


Comments:


CJC Wechat 微信公众号

CJC触屏版


 

Editorial Manager


CC adopts Editorial Manager to manage its submissions from Dec.18, 2014
 

 

Reference style for  

 EndNote,
 Reference Manager



Editorial Manager


 

Year:

 

Month:

Advanced search

Subscription


CJC is now published by BioMed Central

© Chinese Journal of Cancer

Sun Yat-sen University Cancer Center

651 Dongfeng Road East, Guangzhou 510060, P. R. China